DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee

Information source: Endo Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoarthritis, Knee

Intervention: Lidoderm (Drug); Placebo patch (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Endo Pharmaceuticals

Official(s) and/or principal investigator(s):
Study Director, Study Director, Affiliation: Endo Pharmaceuticals


Patients with unilateral or bilateral osteoarthritis (OA) of the knee participated in a Phase II clinical trial to assess the efficacy of lidocaine 5% patch compared with placebo in the treatment of pain from OA of the knee.

Clinical Details

Official title: A Randomized, Double-Blind, Pilot Study Comparing the Efficacy and Safety of Lidocaine 5% Patch With Placebo in Patients With Pain From Osteoarthritis of the Knee

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome:

Western Ontario and McMaster Universities (WOMAC) OA Index

Pain intensity and pain relief (BPI Questions 3, 4, 5, 6, and 8)

Pain Quality Assessment Scale (PQAS)

Patient-rated and Investigator-rated Global Impression of Change in OA pain (categorical scale)

Patient-rated and Investigator-rated Global Assessment of Treatment Satisfaction (categorical scale)

Secondary outcome:

QoL: Pain interference on activities of daily living using Question 9 of the BPI

QoL: Beck Depression Inventory (BDI)

Quality of Sleep (QOS)

Safety assessments included AEs, dermal assessments, clinical laboratory tests (including urinalysis), vital sign measurements, physical examination results, and plasma lidocaine concentrations


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Key Inclusion Criteria: 1. Had unilateral or bilateral OA of the knee diagnosed according to the American College of Rheumatology (ACR) criteria based on clinical and radiographic evidence (presence of osteophytes on x-ray and written evaluation) of OA 2. Had functional capacity class rating of I, II, or III according to ACR classification 3. Had normal 12-lead electrocardiogram (ECG) without any clinically significant abnormalities in heart rate, rhythm, or conduction 4. Had discontinued use of all analgesic medications (including over-the-counter [OTC] analgesics) prior to randomization (patients were allowed limited use of analgesic medications for non study pain 5. At baseline visit, patients were randomized to double-blind treatment if they had an average pain intensity rating for the index joint of 6 or greater (on a 0 to 10 scale) for at least 3 days out of the 5 consecutive days immediately prior to the baseline visit; 0 is defined as "no pain" and 10 is defined as "pain as bad as ever imagined" as measured by Question 5 of the BPI and recorded in a diary 6. At baseline visit, patients were randomized to double-blind treatment if they had, at the baseline visit, an OA severity score for the index joint of 7 or greater on a composite scale of 0 to 24 as measured by the Index of Severity for Osteoarthrosis of the Knee Key Exclusion Criteria: 1. Had been diagnosed with inflammatory arthritis, gout, pseudo-gout or Paget's disease that in the investigator's opinion would have interfered with the assessment of pain and other symptoms of OA 2. Had serious medical conditions requiring daily medications, such as anticonvulsants and tricyclic antidepressants, that could have confounded study results 3. Had any other clinically significant joint disease or prior joint replacement surgery at the index joint 4. Had severe renal insufficiency (creatinine clearance of <30 mL/min) 5. Had moderate or greater hepatic impairment 6. Were taking analgesic medications, glucosamine, or chondroitin that could not be discontinued during the study. Patients taking these medications prior to the study were required to discontinue use for the duration of the study. Patients using opioid analgesics at study entry were required to taper off these medications. 7. Were taking long-acting opioids or opioids that could not be discontinued over the first 5 days of the placebo run-in period. 8. Were using lidocaine-containing product that could not be discontinued during the study 9. Had previously failed treatment with Lidoderm analgesic patch for OA 10. Had recently received either a corticosteroid injection (within 8 weeks) or hyaluronic acid (within 6 months) of study entry 11. Were unable to discontinue use of topical drugs applied to the knee 12. Were taking class I anti-arrhythmic drugs (e. g. mexiletine, tocainide)

Locations and Contacts

Birmingham, Alabama, United States

Hueytown, Alabama, United States

Tallassee, Alabama, United States

Phoenix, Arizona, United States

Boulder, Colorado, United States

Deland, Florida, United States

Largo, Florida, United States

Palm Harbor, Florida, United States

St. Petersburg, Florida, United States

Chicago, Illinois, United States

Springfield, Illinois, United States

Wheaton, Maryland, United States

Peabody, Massachusetts, United States

Bingham Farms, Michigan, United States

Reno, Nevada, United States

Berlin, New Jersey, United States

Dayton, Ohio, United States

Oklahoma City, Oklahoma, United States

Duncansville, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Charleston, South Carolina, United States

Bartlett, Tennessee, United States

Cordova, Tennessee, United States

Memphis, Tennessee, United States

Additional Information

Starting date: August 2004
Last updated: February 9, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017